PTSDNFTIPNCT02544971
Neurofeedback Therapeutic Intervention For Post-Traumatic Stress Disorder Patients Compared To Treatment As Usual
A study testing Neurofeedback in people with PTSD, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
Trial summary
Post-traumatic stress disorder (PTSD) is a common debilitating disorder that affects many individuals exposed to aversive events. The severity of PTSD symptoms is positively correlated with amygdala activation. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- PTSD
- What is being tested?
- Neurofeedback
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteIsrael
- Study dates
- Apr 2016to Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of chronic Post traumatic stress disorder (PTSD) (at least one year and two months since diagnosis; diagnosis according to DSM-V, or DSM-VI)
- Patients must meet the criteria for medical MRI testing set by Tel Aviv Sourasky Medical Center
Who cannot join
- Patients diagnosed with another major psychiatric disorder other than PTSD (such as schizophrenia).
- Patients diagnosed with substance abuse.
- Any aggravation of PTSD symptoms that requires hospitalization.
- Patients who are unable to commit to the duration and plan of the study.
- Patients who meet the criteria for exclusion in medical MRI scans, according to procedures set forth at MRI Medical Center in Tel-Aviv Sourasky. For example, metal that cannot be removed, orthodontal accessories connected to one's teeth, or current systemic diseases.
Trial locations and contacts
1 site in 1 country.
Israel1 site
Whol Institute for Advanced Imaging, Tel Aviv Sourasky Medical Center
Tel Aviv
About this study
Post-traumatic stress disorder (PTSD) is a common debilitating disorder that affects many individuals exposed to aversive events. The severity of PTSD symptoms is positively correlated with amygdala activation. More severe PTSD symptoms following exposure to stressful events, are associated with amygdala hyper-responsivity prior to exposure. A possible intervention for PTSD is Neurofeedback (NF) - a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Previous work in our lab established a NF training procedure that utilizes the temporal abilities of EEG with the spatial advantages of fMRI. Further work based on this method using the amygdala BOLD signal (EEG-finger-print, EFP) has demonstrated a potential for improving the ability to self-regulate amygdala activity and to improve emotional regulation in a healthy population. The current study aims to investigate the potential of this method as a therapeutic intervention for PTSD.
Read the detailed description
Pre-treatment phase (one week) Day 1 Participants will arrive at Tel Aviv Sourasky Medical Center (TASMC) and receive an explanation regarding the study and protocol and will sign informed consent. They will then be asked to fill demographic and psychological questionnaires assessing emotion regulation abilities (ERQ), state and trait anxiety (STAI), and questionnaires measuring symptoms of stress, anxiety and depression such as BDI. They will also be interviewed using clinically structured interviews (SCID, CAPS).
All participants will undergo psychiatric evaluation in the trauma clinic at TASMC. The evaluation would also entail medication monitoring.
The participants would be randomized to the three groups NF-T group (N=20), NF-N group (N=20) and treatment as usual (N=20), based on: age (under/over 40) and time since traumatic event (over or under 5 years).
Day 2 All participants will undergo a brain-imaging scan to characterize brain network responses associated with emotional arousal and regulation. Participants will be scanned for functional and structural MRI, which will include ROI localizer for the neurofeedback (NF), resting state and diffusion tensor imaging (DTI). Following which participants of the NF treatment groups will have 1 session of real-time-functional MRI-electric fingerprint neurofeedback (rt-fMRI-EFP NF) session.
Prior to this session a research staff member will explain the course of the MRI testing to the participant, and will enter with the participants into the mock simulator to verify that he or she is lying on their back properly and feel comfortable. During scanning the patient will be presented with visual and auditory stimuli, as well as short video clips. Auditory presentation: stimuli will be heard via MRI -compatible headphones. Visual displays: the participants will view the stimuli through a mirror and projected onto a screen in the magnet room. In between blocks the participants will be given time to rest. Participants will be asked to avoid moving as much as possible during the scans.
The total duration of testing, from participant arrival to departure, will take approximately 90-180 minutes (20-30 minutes to fill out forms and undergo training, 30 minutes for explanations and a break, and 60 minutes of imaging). Participants will remain in the MRI for about 60 minutes, and under no circumstances will remain longer than 90 minutes.
Treatment phase (12 weeks) The duration of the treatment phase will be 12 weeks. All groups will receive 1/2 sessions per week.
Treatment as usual sessions: Participants will obtain their regular treatment regimen (pharmacological and/or psychological) and meet with a psychologist/psychiatrist following the common practice in the clinic.
NF-EFP sessions: For the duration of each NF-EFP session the participant will be seated comfortably in front of a computer screen. A staff member will explain the goal of the meeting to the participant, present the equipment to be used and describe the course of the meeting. Following the above explanations, the staff member will place the EEG cap on the participants head and ensure that he/she feels comfortable. The EEG-NF practice will consist of about five-minute segments repeated for up to 30 minutes. During each practice segment the participant will be asked to modify visual or auditory media that provides feedback on the degree of successful brain training. For example, during visual feedback the participants will be asked to slow the speed of a skateboard presented on the computer screen or alternatively, via auditory feedback, to reduce the intensity of auditory stimuli audible through the headphones. The duration of one session is approximately 45 minutes.
NF-EFP sessions for the NF-N group: The participants will receive about one or two sessions per week as described above. All training sessions will be held in a neutral, non trauma-related, context.
NF-EFP sessions for the NF-T group: The use of trauma-related context in this group will be done gradually to ensure participants gain control over the feedback training. In the first phase that will include about 6 out of 12 sessions, the participants will train in NF sessions identical to those of the NF-N group. Participants who succeed in lowering EFP signal during training (compared to baseline) in 4 out of 6 sessions, or in the last 3 out of 5 sessions, will qualify to continue to the next phase of training. In the second phase, participants who succeed as described above, will train in the context of their traumatic story. In the first session, the participants will listen to a recording of their trauma, accompanied by one of the team members with relevant training, and will immediately train on emotional regulation using NF in a neutral context. Participants that succeed in down regulation of their EFP signal in at least one session will continue to the next trauma-context sessions. In these sessions, the feedback indicating the EFP signal would be the volume of the trauma-recording. That is, a successful reduction of EFP signal would reduce the volume of the trauma recording. Participants who don't succeed in down regulating their EFP signal (with the neutral context) immediately after listening to the trauma-recording will try again in the following NF-N session.
Midpoint assessment (one week) All participants will receive a second psychological evaluation (plus medication monitoring), will complete the questionnaires described in the pre treatment phase.
Post treatment phase (one week) Day 1 All participants will undergo a final psychiatric evaluation, and medication monitoring.
Day 2 All participants will be scanned for functional and structural MRI which will include the resting state DTI and the NF session. They will then complete the same questionnaires as in the pre treatment phase.
- Conditions
- PTSD
- Being tested
- Neurofeedback, Control
- Medical subject headings
- Stress Disorders, Post-Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NeurofeedbackBehavioural
Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
ControlOther
Treatment as usual
| Study group | Role | What they receive |
|---|---|---|
| NF-N group | Experimental | Neurofeedback in a neutral context Receives: Behavioral: Neurofeedback |
| NF-T group | Active comparator | Neurofeedback in a trauma-related context Receives: Behavioral: Neurofeedback |
| Control group | Active comparator | Treatment as usual Receives: Other: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Decreased PTSD symptoms measured by change in psychiatric evaluation and PCL score
Psychiatric evaluation is based on amount and severity of symptoms according to DSM-IV/V. We will also base change in symptoms on a statistically significant change in PCL (PTSD Check List) score
Measured: 1-14 weeks
Reduced amygdala reactivity measured by percent change in BOLD signal
Measured: 1-14 weeks
Secondary outcomes (3)
Change in Emotion Regulation Questionnaire (ERQ)
36-item measure of cognitive coping strategies
Measured: 1-14 weeks
Change in State/Trait Anxiety Inventory (STAI)
20-item measure of state \& trait anxiety
Measured: 1-14 weeks
Change in Beck Depression Inventory (BDI-II)
21-item measure of clinical depression
Measured: 1-14 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2015 (estimated)
- Study startApr 2016
- Primary completionNov 2018 (estimated)
- Study completionJun 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PTSDStudies of the same condition, open and under way.
- More trials run by Tel-Aviv Sourasky Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Talma Hendler, MD, PhD, Principal investigator, Tel Aviv University Sourasky Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02544971
- Sponsor's protocol ID
- 0215-15-TLV
- Acronym
- NFTIP
- Status last verified
- Mar 2018
- First submitted
- 3 Sep 2015
- Last updated
- 6 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neurofeedback Therapeutic Intervention For Post-Traumatic Stress Disorder Patients Compared To Treatment As Usual
- ClinicalTrials.gov ID
- NCT02544971
- Acronym / sponsor ID
- NFTIP / 0215-15-TLV
- Conditions
- PTSD
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Tel-Aviv Sourasky Medical CenterOther government
- Study start
- Apr 2016 (actual)
- Primary completion
- Nov 2018 (estimated)
- Study completion
- Jun 2019 (estimated)
- First posted
- 9 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Post-traumatic stress disorder (PTSD) is a common debilitating disorder that affects many individuals exposed to aversive events. The severity of PTSD symptoms is positively correlated with amygdala activation. More severe PTSD symptoms following exposure to stressful events, are associated with amygdala hyper-responsivity prior to exposure. A possible intervention for PTSD is Neurofeedback (NF) - a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Previous work in our lab established a NF training procedure that utilizes the temporal abilities of EEG with the spatial advantages of fMRI. Further work based on this method using the amygdala BOLD signal (EEG-finger-print, EFP) has demonstrated a potential for improving the ability to self-regulate amygdala activity and to improve emotional regulation in a healthy population. The current study aims to investigate the potential of this method as a therapeutic intervention for PTSD.
Detailed description
Pre-treatment phase (one week) Day 1 Participants will arrive at Tel Aviv Sourasky Medical Center (TASMC) and receive an explanation regarding the study and protocol and will sign informed consent. They will then be asked to fill demographic and psychological questionnaires assessing emotion regulation abilities (ERQ), state and trait anxiety (STAI), and questionnaires measuring symptoms of stress, anxiety and depression such as BDI. They will also be interviewed using clinically structured interviews (SCID, CAPS).
All participants will undergo psychiatric evaluation in the trauma clinic at TASMC. The evaluation would also entail medication monitoring.
The participants would be randomized to the three groups NF-T group (N=20), NF-N group (N=20) and treatment as usual (N=20), based on: age (under/over 40) and time since traumatic event (over or under 5 years).
Day 2 All participants will undergo a brain-imaging scan to characterize brain network responses associated with emotional arousal and regulation. Participants will be scanned for functional and structural MRI, which will include ROI localizer for the neurofeedback (NF), resting state and diffusion tensor imaging (DTI). Following which participants of the NF treatment groups will have 1 session of real-time-functional MRI-electric fingerprint neurofeedback (rt-fMRI-EFP NF) session.
Prior to this session a research staff member will explain the course of the MRI testing to the participant, and will enter with the participants into the mock simulator to verify that he or she is lying on their back properly and feel comfortable. During scanning the patient will be presented with visual and auditory stimuli, as well as short video clips. Auditory presentation: stimuli will be heard via MRI -compatible headphones. Visual displays: the participants will view the stimuli through a mirror and projected onto a screen in the magnet room. In between blocks the participants will be given time to rest. Participants will be asked to avoid moving as much as possible during the scans.
The total duration of testing, from participant arrival to departure, will take approximately 90-180 minutes (20-30 minutes to fill out forms and undergo training, 30 minutes for explanations and a break, and 60 minutes of imaging). Participants will remain in the MRI for about 60 minutes, and under no circumstances will remain longer than 90 minutes.
Treatment phase (12 weeks) The duration of the treatment phase will be 12 weeks. All groups will receive 1/2 sessions per week.
Treatment as usual sessions: Participants will obtain their regular treatment regimen (pharmacological and/or psychological) and meet with a psychologist/psychiatrist following the common practice in the clinic.
NF-EFP sessions: For the duration of each NF-EFP session the participant will be seated comfortably in front of a computer screen. A staff member will explain the goal of the meeting to the participant, present the equipment to be used and describe the course of the meeting. Following the above explanations, the staff member will place the EEG cap on the participants head and ensure that he/she feels comfortable. The EEG-NF practice will consist of about five-minute segments repeated for up to 30 minutes. During each practice segment the participant will be asked to modify visual or auditory media that provides feedback on the degree of successful brain training. For example, during visual feedback the participants will be asked to slow the speed of a skateboard presented on the computer screen or alternatively, via auditory feedback, to reduce the intensity of auditory stimuli audible through the headphones. The duration of one session is approximately 45 minutes.
NF-EFP sessions for the NF-N group: The participants will receive about one or two sessions per week as described above. All training sessions will be held in a neutral, non trauma-related, context.
NF-EFP sessions for the NF-T group: The use of trauma-related context in this group will be done gradually to ensure participants gain control over the feedback training. In the first phase that will include about 6 out of 12 sessions, the participants will train in NF sessions identical to those of the NF-N group. Participants who succeed in lowering EFP signal during training (compared to baseline) in 4 out of 6 sessions, or in the last 3 out of 5 sessions, will qualify to continue to the next phase of training. In the second phase, participants who succeed as described above, will train in the context of their traumatic story. In the first session, the participants will listen to a recording of their trauma, accompanied by one of the team members with relevant training, and will immediately train on emotional regulation using NF in a neutral context. Participants that succeed in down regulation of their EFP signal in at least one session will continue to the next trauma-context sessions. In these sessions, the feedback indicating the EFP signal would be the volume of the trauma-recording. That is, a successful reduction of EFP signal would reduce the volume of the trauma recording. Participants who don't succeed in down regulating their EFP signal (with the neutral context) immediately after listening to the trauma-recording will try again in the following NF-N session.
Midpoint assessment (one week) All participants will receive a second psychological evaluation (plus medication monitoring), will complete the questionnaires described in the pre treatment phase.
Post treatment phase (one week) Day 1 All participants will undergo a final psychiatric evaluation, and medication monitoring.
Day 2 All participants will be scanned for functional and structural MRI which will include the resting state DTI and the NF session. They will then complete the same questionnaires as in the pre treatment phase.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| NF-N group | Experimental | Behavioral: NeurofeedbackNeurofeedback in a neutral context |
| NF-T group | Active comparator | Behavioral: NeurofeedbackNeurofeedback in a trauma-related context |
| Control group | Active comparator | Other: ControlTreatment as usual |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Diagnosis of chronic Post traumatic stress disorder (PTSD) (at least one year and two months since diagnosis; diagnosis according to DSM-V, or DSM-VI)
- Patients must meet the criteria for medical MRI testing set by Tel Aviv Sourasky Medical Center
Key exclusion criteria (5 listed)
- Patients diagnosed with another major psychiatric disorder other than PTSD (such as schizophrenia).
- Patients diagnosed with substance abuse.
- Any aggravation of PTSD symptoms that requires hospitalization.
- Patients who are unable to commit to the duration and plan of the study.
- Patients who meet the criteria for exclusion in medical MRI scans, according to procedures set forth at MRI Medical Center in Tel-Aviv Sourasky. For example, metal that cannot be removed, orthodontal accessories connected to one's teeth, or current systemic diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NeurofeedbackNeurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop. | Behavioural | NF-N group, NF-T group |
| ControlTreatment as usual | Other | Control group |
Primary outcome
Decreased PTSD symptoms measured by change in psychiatric evaluation and PCL score
Time frame: 1-14 weeks
Psychiatric evaluation is based on amount and severity of symptoms according to DSM-IV/V. We will also base change in symptoms on a statistically significant change in PCL (PTSD Check List) score
Reduced amygdala reactivity measured by percent change in BOLD signal
Time frame: 1-14 weeks
3 secondary outcomes
Change in Emotion Regulation Questionnaire (ERQ)
Time frame: 1-14 weeks
Change in State/Trait Anxiety Inventory (STAI)
Time frame: 1-14 weeks
Change in Beck Depression Inventory (BDI-II)
Time frame: 1-14 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2018.
Related trials for PTSD
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Not yet recruitingPhase 3
Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol
Post-Traumatic Stress Disorder, PTSD
RecruitingPhase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Insomnia, PTSD
Recruiting
Advancing Skills Through Consultation, Education, and Novel Technologies
PTSD - Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Talma Hendler, MD, PhD principal investigator
Tel Aviv University Sourasky Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neurofeedback in people with PTSD, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Decreased PTSD symptoms measured by change in psychiatric evaluation and PCL score (time frame: 1-14 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2018.